NervGen Pharma Corp. NGEN
1.96 USD +0.14 (+7.69%)
Regular-session close
1.98 +0.02 +1.02%
After hours · Nov 17, 6:00 PM ET
1.80 Day range 2.08
1.28 52-week range 6.30
- YTD
- -65.00%
- 1 year
- -16.24%
- Market cap
- 210.93M
- EPS (ttm)
- -0.57
- YTD return
- -65.00%
- 1-year return
- -16.24%
- Volume
- 1.72M
- Avg volume
- 582.37K
- Open
- 1.81
- Previous close
- 1.82
- Day's range
- 1.80 – 2.08
- 52-week range
- 1.28 – 6.30
5D +0.60 (+44.12%)
Fundamental scorecard
5 of 25 checks passed on NGEN’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
NGEN Revenue — quarterly 0
NGEN Net income — quarterly 10.80M
NGEN EPS — quarterly 0.12
News
NervGen Pharma Q3 EPS $(0.04) Beats $(0.12) Estimate
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
NervGen Pharma (NASDAQ:NGEN) Stock Has Consensus Price Target of $14.00 According to Brokerages
Your note
Sign in to keep a note on NGEN — it syncs with the Stock Master app.
